Royalty Report: Medical, Stem cells, Drugs – Collection: 297144

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Medical
  • Stem cells
  • Drugs
  • Biotechnology
  • cell therapy
  • Drug Discovery
  • Specialty
  • Supply
  • Therapeutic
  • Cancer
  • Device
  • Packaging & Containers
  • Storage
  • Disease
  • bone marrow
  • Research
  • Test/Monitoring

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 297144

License Grant
The Company acquired an exclusive license (and a right to sub-license) to the technology and know-how relating to an isolation and commercial scale expansion methodology of GMP grade human umbilical cord mesenchymal stem/stromal cells (“MSC”).
License Property
Mesenchymal stem cells (“HucMSC”) – a methodology for producing large numbers of clinical-grade pooled human umbilical cord.

Mesenchymal stem cells is for the medical research and biotech community that offers large volumes of high-quality, low passage human umbilical cord mesenchymal stem cells with minimal batch-to-batch variability.

Field of Use
This agreement pertains to the medical industry relating to stem cells.

IPSCIO Record ID: 246210

License Grant
The Licensor grants the Licensee an exclusive licence to use, process, test and store the Materials (umbilical cord tissue samples) and Mesenchymal Stem Cells;  produce Licensed Product, including the creation of Derivatives and Progeny from Materials;  supply Licensed Product to third parties and to provide services in relation to such Licensed Product to third parties; and sub-licence its rights to Affiliates and to third party service providers.
License Property
The procurement of Mesenchymal Stem Cells derived from umbilical cord blood or placenta to be used for research purposes.  Materials are only for use in humans or for human application.
Field of Use
Cord Blood/Tissue, derived cells, progeny or derivative may be supplied and used in research projects if conducted in accordance with certain conditions.

License is for the methodology for producing clinical-grade pooled human umbilical cord derived mesenchymal stem/stromal cells (“HucMSC”) at industrial scale.

IPSCIO Record ID: 340079

License Grant
The Agreement grants the patent rights. The contract grants Licensee access to proprietary process of expanding the master cell bank of Licensor.
License Property
9,803,176 – The Patent is titled Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses.
Field of Use
The field of use means transwell/co culture is for enhancing autologous cell stem cells.

The transwell migration assay is a commonly used test to study the migratory response of endothelial cells to angiogenic inducers or inhibitors. This assay is also known as the Boyden or modified Boyden chamber assay.

IPSCIO Record ID: 273421

License Grant
The Parties reached a mutual understanding that the License Agreement drafted in 2001 no longer accurately reflected the business model of the Licensee, and that it contained certain restrictions and milestones that were not optimal for the commercialization of the Invention portfolio.

With this amendment, The University Regents grant a world-wide license under The Universitys undivided interest in Patent Rights to make, have made, use, sell, offer to sell and import Product and to practice Licensed Method in the Field.

License Property
This license is for certain inventions, generally characterized as Adipose-Derived Stem Cells and Lattices.

The patents include Isolation of Stromal Cells from Adipose Tissue, Isolation of Mesenchymal Stem Cells from Adipose Tissue, and, Adipose-Derived Stem Cells and Lattices.

Product means Research Product and Clinical Product.

Field of Use
The Field means any and all products and/or services for the research, diagnosis, and/or therapy of disease and/or disorders in humans and for cosmetic applications in humans.

Licensee is commercializing an automated device called Celution, which when operated in conjunction with various disposable component parts is capable of producing a heterogeneous isolate of the material naturally occurring in adipose tissue including unmodified amounts of stem cells and other regenerative cells, intended for human therapeutic, diagnostic, cosmetic and other uses.

The patented Celution® family of products process patients’ adipose-derived stem and regenerative cells (ADRCs) at the point of care. The Celution® family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation.  Licensee commercialization model is based on the sale of Celution® Systems and on generating recurring revenues from the single-use consumable sets.

Commercial activities are currently focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, where Cytori’s core product, the Celution® System, provides physicians with clinical grade stem and regenerative cells.

IPSCIO Record ID: 345978

License Grant
University has granted to the Company an exclusive license to make, have made, use, import, offer for sale, sell and otherwise commercially exploit (with the right to sublicense) certain licensed products and to practice certain licensed processes, and the exclusive right to use certain regulatory data and technical information in connection with such licensed patent rights, in the treatment, prevention, cure, reduction, mitigation or other management of certain diseases in humans, except, with regard to certain patent rights, in certain excluded fields of use and in certain territories, subject to University’s reserved rights to practice the licensed rights for all research, public service, internal (including clinical) and/or educational purposes.
License Property
The licensed products and patent rights are related to cord blood and cord tissue.
Field of Use
Field of use is for the treatment, prevention, cure, reduction, mitigation or other management of certain diseases in humans relating to the cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use.

IPSCIO Record ID: 47933

License Grant
The Spanish University patent families referred to as PCX006 and PCX007 are the subject of a co ownership agreement with the Spanish Licensee. Under the terms of this agreement, the University assigned all exploitation rights, including the right to license or sub-license to third parties.
License Property
University signed an agreement for the Assignment of the Rights to Exploit Spanish invention patents no. 200402355, entitled “IDENTIFICATION AND ISOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE”, and no. 200402083, entitled “Biomaterial for suture”

PCX006 is a patent family claiming a non osteochondral derived multipotent adult stem cell population characterized by a set of biological markers.
PCX007 is a patent family claiming an adipose derived stem cell composition characterized by a panel of cell surface markers, methods of preparation of such a composition and adipose tissue derived stromal stem cells in treating fistula and wounds.

(WO2006037649/11/167,061) IDENTIFICATION AND INSOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE
The present invention relates to isolated multipotent adult cells which are isolated from non-osteochondral mesenchymal tissue and are characterized by the presence and absence of a set of cell surface markers. The invention also relates to a method for identifying and isolating a population of said cells, as well as to the applications thereof, for example, in the manufacture of a pharmaceutical composition for the repair and regeneration of tissues.

Field of Use
The Licensee is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from our proprietary technology platforms of allogeneic, or donor-derived, stem cells.

IPSCIO Record ID: 382728

License Grant
German Licensor granted an exclusive license in the field of certain human stem cells.
License Property
Human stem cells relates to replacing damaged tissues and to help the body regenerate after injury.

Licensor has the unique strength of combining stem cell research focused on different organs and developmental stages with leading expertise in cellular plasticity, epigenetics and disease models. This unique combination has led to breakthrough discoveries at the crossroads between disease models and repair, cellular plasticity and disease as well as reprogramming.

Field of Use
Field of use is used in the medical industry relating to stem cells.

IPSCIO Record ID: 383557

License Grant
Licensor grants the Licensee of Japan an exclusive license in the Territory, with the right to grant sublicenses, under the Licensor Patents and Licensor Technology to develop, register and to obtain Product Registrations, use, make, have made, import, export, offer to sell, sell and have sold Products for use in the Field in the Territory.
License Property
Licensor is the owner of certain technology, including, but not limited to patents and know-how, relating to mesenchymal stem cells.

MSC shall mean human cells that are capable of differentiation into more than one mesenchymal lineage.

Product means any product or composition that contains MSC and/or any process or service performed with respect to recovery, expansion, maintenance, purification, storage, production, formulation or use of MSC.

The patents include
—  Monoclonal antibodies specific for marrow-derived mesenchymal cells;
—  Uses for non-autologus mesenchymal stem cells;
—  Osteoporosis bond regeneration;
—  Mesenchymal stem cells for prevention and treatment of immune responses in transplantation;
—  Mesenchymal stem cells as immunosuppressants;
—  Regulation of Hema topoietic stem cell  differentiation by the use of human mesenchymal stem cells;
—  Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation.

Field of Use
The Field means the use of MSC in or in conjunction with the treatment of hematological malignancies by the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow.

Hematologic malignancies are cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. There are three main types of hematologic malignancies leukemia, lymphoma and multiple myeloma.

IPSCIO Record ID: 383612

License Grant
Licensor grants an exclusive, even as to Licensor, except as required for Licensor to meet its development and supply obligations hereunder, right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property and Licensors interest in any Joint Patent Rights and Joint Technology solely to research, develop, make, have made, use, sell, offer for sale and import Products in the Field in the Licensee Territory, and a non-exclusive right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property to research, make, have made, use and export Products in the Field in North America.
License Property
Licensor is a stem cell therapeutic leader focused on developing and marketing products to treat medical conditions and possesses broad scientific and clinical leadership in the field of human mesenchymal stem cells (MSCs) and know-how, expertise and intellectual property rights pertaining to MSCs, including its Prochymal product and Chondrogen product.

Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.

Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.

Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.

Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.

COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.

Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.

Crohns Indication shall mean the use of Prochymal to treat Crohns disease.

Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.

GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.

Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.

Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.

Field of Use
Field shall mean with respect to Prochymal, all applications for the prevention or treatment of diseases, defects, or conditions in humans, and with respect to Chondrogen, the Articulating Orthopedic Indication.

IPSCIO Record ID: 204653

License Grant
Israeli University granted to Licensee an exclusive license to (i) the inventions, know-how and results made with respect to the stem cell technology developed by the team led in the course of the performance of the research, and the patents and pending patent applications owned by University, and (ii) the results of further research to be performed by the same team on the development of the stem cell technology.
License Property
The inventions, know-how and results made with respect to the stem cell technology relating to processes for the transformation of bone marrow and cord blood stem cells into neuron-like and glial-like cells.
Field of Use
This agreement pertains to stem cell technology.

IPSCIO Record ID: 47833

License Grant
Two Spanish Licensors, including a University, have an exclusive license agreement with a Spanish Licensee of all rights to the Patent.
License Property
The agreement is for a patent under number PCT/IB2009/006597 entitled Uses of Mesenchymal Stem Cells. Licensee has the intention of applying for future international extensions of such application, hereinafter, all of them jointly referred to as the Patent.
Field of Use
Systemic inflammatory response syndrome (SIRS) is an inflammatory state of the whole body without a specific source of infection. It can be caused by many factors, including but not limited to trauma, surgery, adrenal insufficiency, pulmonary embolism, myocardial infarction, hemorrhage, anaphylaxis, drug overdose, immunodeficiency and burns. There are four major diagnostic symptoms of SIRS, as listed below, but the presence of any two of these is sufficient for a diagnosis.

IPSCIO Record ID: 307629

License Grant
The Option grants the exclusive option to obtain an exclusive license to certain of University’s patent rights to make, have made, use, import, offer for sale, sell and otherwise commercially exploit certain licensed products and to practice certain licensed processes, and the exclusive right to use certain regulatory data and technical information in connection with such licensed patent rights, in the treatment, prevention, cure, reduction, mitigation or other management of diseases in humans, except, with regard to certain patent rights, in certain excluded fields of use and in certain territories, as well as a limited license to make, have made or use certain products, processes, data and information for the purpose of evaluating the market potential for such products and processes in the designated field of use, subject to University’s reserved rights to practice the licensed rights for all research, public service, internal (including clinical) and/or educational purposes. Pursuant to the Option, the terms of any such license are to include the terms.

The University grants an exclusive option to obtain
(a) an exclusive worldwide license under Patent Rights B to make, have made, use, import, offer for sale, sell and otherwise commercially exploit Licensed Products and to practice Licensed Processes, and the exclusive right to use regulatory data and technical information in connection with such licensed patent rights, in the Field of use and Territory; and
(b) an exclusive license under Patent Rights A to make, have made, use, import, offer for sale, sell and otherwise commercially exploit Licensed Products and to practice Licensed Processes, and the exclusive right to use Regulatory Data and Technical Information in connection with such licensed patent rights, in the Field of Use and Territory except for the Excluded fields of uses in the Excluded Territory.

License Property
The Option is for patent rights, regulatory data, and proprietary processes related to cord blood, cord tissue and DUOC-01.

Patent Rights Group (A) include

•
METHODS OF TREATING BRAIN INJURY USING CORD BLOOD OR A COMPONENT THEREOF,

•
COMPOSITIONS AND METHODS OF THE TREATMENT OF DEMYLINATING CONDITIONS,
        â€¢
METHODS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS,
Patent Rights Group (B) include

•
METHODS OF TREATING CEREBRAL PALSY USING HIGH DOSE ALLOGENEIC UMBILICAL CORD BLOOD,

•
METHODS OF TREATING CEREBRAL PALSY AND HYPOXIC-ISCHEMIC ENCEPHALOPATHY USING HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS,
       •
METHODS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS USING HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS,
       •        COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEMYELINATING CONDITIONS
       •
COMPOSITIONS COMPRISING MESESCHYMAL STROMAL CELLS FOR THE TREATMENT OF VIRAL INFECTIONS

Field of Use
The Field of Use for the proprietary processes related to cord blood and cord tissue means the treatment, prevention, cure, reduction, mitigation or other management of any and all diseases and conditions in humans.  The Excluded Fields of Use means autologous specific therapeutics for autism, cerebral palsy and stroke.

Option agreement brings novel cord blood and birthing tissue based cellular therapeutics to the clinic.

The company services include the cryopreservation of umbilical cord blood and cord tissue. The company has also patented a method for processing endometrial stem cells from menstrual blood.

IPSCIO Record ID: 4928

License Grant
The Company and the NYBC, as co-licensors, entered into a license agreement in which the Licensees became the exclusive worldwide manufacturers and distributors (excluding Japan) for the system of sterile, medical disposable containers developed by the Company and NYBC for the processing of hematopoietic stem cells sourced from PCB.  Licensor grants to Licensee, under the terms and conditions of this Agreement, an exclusive license within the Exclusive Field of Use and the Non-Exclusive Field of Use under the Licensed Patent Rights and Know-How (a) to make, use, sell, or otherwise dispose of the Licensed Products, and (b) to use the methods covered by the Licensed Patent Rights and Know-How for the manufacture, use and sale of Licensed Products. Licensor retains for itself the right to practice for itself, without the right to sublicense distribution, the Licensed Patent Rights and Know How within the Non-Exclusive Field of Use and to use the methods covered by the Licensed Patent Rights and Know-How.
License Property
Licensor has developed know-how and patent rights for plastic disposable bags or containers for the isolation, collection, processing, freezing and infusion of stem cells for use with placental/umbilical cord blood.

Method of Isolation of Stem Cells and Bag Array U.S. #08/349,747
Improved Bag Design and Method of Manufacturing U.S. #08/670,368

Field of Use
Exclusive  Field  of Use@ shall mean the practice of stem cell  isolation and collection from umbilical cord blood, and the freezing, storage, processing and infusion of such stem  cells.
Non-Exclusive Field of Use@ shall mean all other applications of the Licensed Product.

IPSCIO Record ID: 6088

License Grant
Licensor hereby grants to Licensee a non-exclusive, non-transferable, royalty-bearing license under the Licensed Patents in the Territory.
License Property
The Licensor holds certain patents relating to the storage, expansion and use of hematopoietic stem cells.

a. 'Collection' or 'Collected' means accumulation of or accumulated Cord Blood in a container.

b. 'Cord Blood' means blood or any blood components (including without limitation stem cells) collected from a human umbilical cord and/or placenta.

c. 'Cryopreservative' means an agent capable of preserving at very low temperatures.

d. 'Cryopreserve' means to preserve a material, such as Cord Blood or Stem Cells, by freezing.

e. 'Cryopreserved Blood' means (i) frozen Cord Blood, (ii) frozen and thawed Cord Blood or (iii) any other composition which would, but for this Agreement, infringe one or more claims of the Licensed Patents, in all three instances with or without a Cryopreservative.

g. 'Expanded Stem Cells' means Stem Cells, expanded from Cryopreserved Blood, or Cryopreserved after expansion.

i. 'Licensed Patents' means U.S. Patents Nos. 5,004,681, 5,192,553, 6,461,645, 6,569,427 and 6,605,275 and all patents that are related to any or all of those patents through priority or otherwise, directly or indirectly, including but not limited to, continuations, continuations in part, divisions, reissues and reexaminations thereof, and shall further include any other.

j. 'Licensed Process' means any process for the Collection, storage or use of Cord Blood that would, but for this Agreement, infringe one or more claims of Licensed Patents.

k. 'Modified Stem Cells' means Stem Cells, modified from Cryopreserved Blood, or Cryopreserved after modification.

Field of Use
The Licensee has the right to collects, processes and stores cord blood utilizing the Licensor's technology and processes covered by its patents for so long as the patents may remain in effect.

IPSCIO Record ID: 3056

License Grant
The Licensor entered into a License Agreement with the Licensee to establish and market the Licensor's U-Cord business in Germany with the option to expand the Licensed territory to include Italy, Spain and France.
License Property
The Licensor is engaged in cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord (U-Cord®) blood stem cells for family use.
Field of Use
The Licensee has been providing families an opportunity to cryogenically preserve their newborn's umbilical cord blood stem cells in a safe and secure environment. This service is called U-Cord.

IPSCIO Record ID: 336338

License Grant
Licensor, a non-profit health care organization, grants to Licensee the worldwide and exclusive license with a right to sublicense, under the Patent Rights, to make, have made, use, have used, offer for sale, have offered for sale, import, have imported, have sold and sell the Licensed Products, and to practice the Licensed Processes, in the Territory for the Field of Use to the end of the Term, unless sooner terminated as provided in this Agreement.
License Property
Rights relate to therapeutic compositions of modulated HSCs and methods for promoting reconstitution of the hematopoietic system using modulators of the prostaglandin pathway.

Licensor is the co-owner with a Hospital Corporation of certain Patent Rights.  The patents are Method to Modulate Hematopoietic Stem Cell Growth, and, Method to Enhance Tissue Regeneration.

ZON IND shall mean the investigational new drug application titled A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using Ex-Vivo 16,16 Dimethyl-Prostaglandin E2 Expanded Umbilical Cord Blood Units.

Field of Use
Licensee's HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, or HSCs, which are adult stem cells that regenerate all types of blood cells throughout a person’s lifespan. HSCs have been used for decades in a potentially curative procedure called hematopoietic stem cell transplant, or HSCT. This procedure is most commonly used in patients with hematologic malignancies to replace a diseased hematopoietic system with a healthy one. While over one million HSCT procedures have been performed to date, we believe HSCs have not been pharmacologically optimized to improve patient outcomes. Licensee'sHSC modulation platform has the potential to generate products that will improve patient outcomes in orphan indications by enhancing hematopoietic reconstitution through accelerated, durable engraftment, permitting greater donor matching flexibility, reducing the risk of major side effects and enabling the use of less toxic conditioning regimens.

Licensee's lead product candidate, ProHema, is a pharmacologically modulated HSC therapeutic derived from umbilical cord blood. Licensee has established human proof-of-concept for ProHema in the clinical setting by demonstrating enhanced and durable engraftment of HSCs within the bone marrow. Engraftment, which is the localization and integration of HSCs within a targeted tissue where they can produce new cells, is an important determinant of patient outcomes in HSCT. Licensee is presently advancing ProHema in Phase 2 clinical development for hematologic malignancies. Licensee is also pursuing the development of pharmacologically optimized HSC therapeutics for the treatment of certain lysosomal storage disorders, or LSDs, where HSCs have demonstrated the ability to home, or migrate, to and engraft within the central nervous system, or CNS.

IPSCIO Record ID: 279305

License Grant
The Licensor of Japan grants a non-exclusive, non-transferable license, without the right to grant or authorize sublicenses except as expressly set forth, under the Licensed Patents to make, have made, use, develop, sell, offer to sell, and distribute, Licensed Pluripotent Cell Product in the Field and in the Territory.

Licensor grants a non-exclusive, non-transferable license, without the right to grant or authorize sublicenses except as expressly set forth, under the Licensed Patents to make, have made, use, develop, sell, offer to sell, and distribute the Licensed Differentiated Cell Products and Licensed Services in the Field and in the Territory.

License Property
Licensed Differentiated Cell Products means any products listed hereto, and any other products which may be added by mutual agreement in writing separately, which are made from induced pluripotent cells produced by methods covered by the Licensed Patents.

Licensed Pluripotent Cell Products means any induced pluripotent stem cell or induced pluripotent stem cell line produced by methods covered by the Licensed Patents.

Licensed Products means both Licensed Differentiated Cell Products and Licensed Pluripotent Cell Products  including Cardiomyocytes, Hematopoeitic cells, Neural cells, Hepatocytes, Endothelial cells, Bone cells, Cartilage, Pancreatic cells, Fat cells and Lung cells.

The iPSC technology was pioneered Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells.

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells.

Field of Use
The iPSC technology turned ordinary human skin cells into pluripotent stem cells, with the same characteristics and potential as embryonic stem cells.
Pluripotent stem cells hold promise in the field of regenerative medicine.[3] Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.

IPSCIO Record ID: 26528

License Grant
The exclusive License is to market the Company’s U-Cord® program.
License Property
The Company is engaged in cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord (U-Cord®) blood stem cells for family use. The Company believes it is the world’s largest family cord blood stem cell bank in terms of the number of specimens preserved.
Field of Use
The rights granted apply in the area of medical technology relating to stem cells.

IPSCIO Record ID: 7349

License Grant
The Licensee entered into a royalty Agreement with the Licensor and received the following assets from the Licensor
License Property
Certain patents and patent applications and all related active prosecution cases, trade secrets, know-how and certain other intellectual property rights, and all of the Licensor's goodwill with respect to the technology directly related to the research, development and commercialization of certain products and know-how related to hES cells;

Certain biological materials and reagents (including master and working cell banks, original and seed banks, and research, pilot and GMP grade lots and finished product);

Certain regulatory filings for clinical trials for GRNOPC-I for spinal cord injury, including the investigational new drug applications filed with the United States Food and Drug Administration for Licensor’s Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury (Protocol No. CP35A007), and long term follow up of subjects who received GRNOPC1 (Protocol No. CP35A008), and the clinical trial for VAC1 for acute myelogenous leukemia, including a Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) in complete remission (Protocol No. CP06-151).

US Patent 6,800,480 – Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
US Patent 7,413,902 – Feeder-Free Culture Method for Embryonic Stem Cells
US Patent 6,440,735 – Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
US Patent 7,402,307 – Method for Identifying and Killing Cancer Cells
US Patent 7,824,849 – Cellular Telomerase Vaccine and Its Use for Treating Cancer
US Patent 7,560,281 – Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
US Patent 8,252,586 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent 8,153,428 – Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
US Patent 6,667,176 – cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
US Patent 7,041,438 – Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
US Patent 7,413,904 – Embryonic Stem Cells Having Genetic Modifications
US Patent 7,410,798 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 7,297,539 – Medium for Growing Human Embryonic Stem Cells
US Patent 7,455,983 – Medium for Growing Human Embryonic Stem Cells
US Patent 8,097,458 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 6,642,048 – Conditioned Media for Propagating Human Pluripotent Stem Cells
US Patent 6,458,589 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 6,506,574 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 7,256,042 – Process for Making Hepatocytes from Pluripotent Stem Cells
US Patent 7,282,366 – Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
US Patent 7,473,555 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent 8,148,151 – Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
US Patent 6,833,269 – Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
US Patent 8,148,148 – Neural Progenitor Cell Populations
US Patent 8,252,585 – Neural Progenitor Cell Populations
US Patent 7,250,294 – Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
US Patent 7,763,463 – Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
US Patent 6,576,464 – Differentiated Cells Suitable For Human Therapy
US Patent 6,921,665 – Selective Antibody Targeting of Undifferentiated Stem Cells
US Patent 7,732,199 – Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,763,464 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent 7,452,718 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,897,389 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,851,167 – Differentiation Protocol for Making Human Cardiomyocytes

US Patent Application 13/561,296 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent Application 12/170,219 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 12/710,078 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 13/323,567 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 11/917,993 – Suspension Culture of Human Embryonic Stem Cells
US Patent Application 12/277,136 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent Application 13/558,078 – Neural Progenitor Cell Populations
US Patent Application 11/359,341 – Differentiated Cells Suitable For Human Therapy
US Patent Application 11/471,916 – Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

Field of Use
The Licensee is a biotechnology company focused on the emerging field of regenerative medicine, with core technologies centered on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency.

IPSCIO Record ID: 346226

License Grant
University granted us an exclusive, worldwide license under such patents and a nonexclusive royalty-bearing, worldwide license for such know-how to research, develop, commercialize and manufacture FCR001 and products containing FCR001 in all fields, without limitation. University also granted us the right to grant sublicenses in accordance with the University License Agreement.
License Property
The rights granted relate to certain licensed patent rights and know-how related to human facilitating cells for the Facilitated Allo-HSCT Therapy.

Aallogeneic hematopoietic stem cell transplantation (allo-HSCT), called Facilitated Allo-HSCT Therapy.  

The product candidate, FCR001, which is central to Facilitated Allo-HSCT Therapy, is a novel allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation. FCR001 is rapidly processed in the GMP facility using proprietary manufacturing methods. Then, at the time of the transplant, FCR001 is administered to the recipient following nonmyeloablative conditioning, which is designed to be less toxic than myeloablative conditioning. A fully myeloablative conditioning regimen consists of a combination of agents and high doses of total body irradiation that destroy hematopoietic stem cells (HSCs) in the bone marrow and results in profound depletion of HSC-derived cells within one to three weeks following administration that is irreversible, and in most instances is fatal unless rescued by a stem cell transplant. The nonmyeloablative conditioning for FCR001 entails lower doses of chemotherapy and total body irradiation, causes less depletion of blood cells and does not require stem cell support for the recipient to resume the production of blood cells and platelets.

Allo-HSCT Therapy has the potential to treat a range of severe autoimmune diseases and severe non-malignant blood, immune and metabolic disorders, in each case with potential for similar outcomes to what has previously been observed with HSCT, while mitigating the toxicities, morbidities and extended hospital stay associated with the conditioning regimen typically required by HSCT.

Field of Use
Field of use is for to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders, in all fields, without limitation.

Facilitated Allo-HSCT Therapy could prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, also known as chronic immunosuppression.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.